Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Expiry of subscription period and last day of trading in subscription rights tomorrow

Financial .2016

(Oslo, Norway, 28 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Bionor Pharma – Share capital increase registered

Financial .2016

(Oslo, Norway, 15 September 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") published on 9 September 2016 regarding the extraordinary general meeting in the Company approving inter alia a share capital reduction and a share capital increase through a private placement of 525,000,000 new shares each at a par value of NOK 0.10 (the "Private Placement").

Expiry of subscription period and last day of trading in subscription rights tomorrow

Financial .2016

(Oslo, Norway, 28 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Mandatory Notification of Trade - Cecilie Grue

Financial .2016

(Oslo, Norway, 27 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

Mandatory Notification of Trade - Sommerfelt

Financial .2016

(Oslo, Norway, 26 September 2016) Reference is made to the announcement on 14 September 2016 by Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue.

Go to news section

Featured content